2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Omics Technologies, Treatment Considerations, Biological Therapies, Infusion, Non-Biological Therapies, Anticoagulant Drugs, Women’s Health, Adverse Events, Biological Processes, Pathogenesis, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality of Care, Diseases, Bleeding and Clotting, Platelet Disorders, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, Genetic Disorders, Lymphoid Malignancies, Lymphomas, Research, Clinical Research, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

3094 Reexamining thrombosis rates in children with congenital heart disease after undergoing cardiac surgery

Anshul Raman, MD, Isabella Zaniletti, PhD2, Amy Kiskaddon, PharmD3, Michael Silvey, DO4
1 Childrens Mercy Kansas City, Kansas City, Missouri, United States, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, United States
2 Children's Hospital Association, Lenexa, Kansas, United States
3 Johns Hopkins All Children's Hospital, St. Petersburg, Florida, United States, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
4 Childrens Mercy Kansas City, Kansas City, Missouri, United States, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, United States

Introduction: Congenital heart disease (CHD) is a common condition affecting 1% of all United States births, with varying degrees of severity, many of which require several surgical procedures to complete repair. The incidence of venous thromboembolism (VTE) in hospitalized pediatric patients has increased over the past 20 years.  A previous retrospective study evaluating children with CHD who develop thrombosis from 2004-2012 demonstrated a steadily increasing thrombosis incidence, as well as high rates of complications (Silvey et al., Thrombosis Research 2017). With the overall increasing incidence of VTEs in the general hospitalized pediatric population, it remains unknown whether this trend has continued, stabilized, or reversed over the subsequent decade in children with CHD and how that has affected length of stay, hospital costs, and overall mortality. 

Objective: To determine the 1-year incidence of thrombosis and the rates of inpatient morbidity and mortality among children with congenital heart disease (CHD) undergoing cardiac surgery (2016-2023), and to compare the current data with the prior study of patients from 2004-2012. 

Materials and methods: We conducted a retrospective cohort study of patients <18 years within the Pediatric Health Information System (PHIS) database who underwent cardiac surgery from 2016-2023. Descriptive statistics were used to estimate outcome rates, and logistic mixed-effects models with a random hospital intercept were used to evaluate the univariable association between procedure type and the primary outcome, 1-year thrombosis.

Results: Among 73,589 CHD patients who underwent cardiac surgery, 2,747 (3.7%) developed thrombosis within 12 months. Thrombosis rate increased from 3.41% in 2016 to 3.95% in 2023, representing a modest but continued upward trend compared to prior years (1.7% in 2004 to 4.4% in 2012). The procedures with higher odds of thrombosis included systemic-to-pulmonary shunt placement [OR 3.46 (95%CI 3.16-3.79), p<0.001], septostomy procedures [OR 2.32 (95%CI 2.07-2.59), p<0.001], Fontan Procedures [OR 1.86 (95%CI 1.7-2.04), p<0.001], total anomalous pulmonary venous return repairs [OR 1.41 (95%CI 1.11-1.79), p=0.005], truncus arteriosus repairs [OR 1.36 (95%CI 1.24-1.49), p<0.001], and tetralogy of Fallot repairs [OR 1.2 (95%CI 1.11-1.31), p<0.001].  Neonates (age <28 days) had the highest thrombosis prevalence, which increased to 73% from 61% in the prior study.  Patients with thrombosis had significantly longer length of stay (median 47 days vs. 8 days, p<0.001) and ICU days (21 vs. 4 days; p<0.001), with higher median adjusted costs ($102,700 vs $25,400; p<0.001).  Thrombosis was significantly associated with bacteremia [OR 4.88 (95%CI 4.3-5.54), p<0.001], endocarditis [OR 3.37 (95%CI 2.67-4.24), p<0.001], and all-cause mortality [12.77% vs 3.05%, p<0.001] in the index encounter.

Conclusions: In this large PHIS cohort, post-surgical thrombosis rates in children with CHD have stabilized compared to the rates observed in 2012, but it has gradually trended upwards from 2016 to 2023. Thrombosis remains associated with greater healthcare utilization, increased rates of infectious complications, and a four-fold higher mortality rate. These findings underscore a need for prospective studies to identify modifiable risk factors to thrombosis and thromboprophylaxis strategies in this vulnerable population.

Anshul Raman, MD: No relevant conflicts of interest to declare.